Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Pyxis Oncology, Inc. before investing.

In this article, we go over a few key elements for understanding Pyxis Oncology, Inc.’s stock price such as:

• Pyxis Oncology, Inc.’s current stock price and volume
• Why Pyxis Oncology, Inc.’s stock price changed recently
• Upgrades and downgrades for PYXS from analysts
• PYXS’s stock price momentum as measured by its relative strength

About Pyxis Oncology, Inc. (PYXS)

Before we jump into Pyxis Oncology, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Want to learn more about Pyxis Oncology, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Pyxis Oncology, Inc..

Pyxis Oncology, Inc.’s Stock Price as of Market Close

As of January 16, 2026, 10:48 AM, CST, Pyxis Oncology, Inc.’s stock price was $1.925.

Pyxis Oncology, Inc. is up 4.64% from its previous closing price of $1.840.

During the last market session, Pyxis Oncology, Inc.’s stock traded between $1.840 and $2.000. Currently, there are approximately 62.56 million shares outstanding for Pyxis Oncology, Inc..

Pyxis Oncology, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Pyxis Oncology, Inc. Stock Price History

Pyxis Oncology, Inc.’s (PYXS) price is currently up 67.43% so far this month.

During the month of January, Pyxis Oncology, Inc.’s stock price has reached a high of $2.170 and a low of $1.085.

Over the last year, Pyxis Oncology, Inc. has hit prices as high as $5.550 and as low as $0.833. Year to date, Pyxis Oncology, Inc.’s stock is up 67.43%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Pyxis Oncology, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of January 15, 2026, there were 6 analysts who downgraded Pyxis Oncology, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Pyxis Oncology, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Pyxis Oncology, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Pyxis Oncology, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Pyxis Oncology, Inc. (PYXS) by visiting AAII Stock Evaluator.

Relative Price Strength of Pyxis Oncology, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 15, 2026, Pyxis Oncology, Inc. has a weighted four-quarter relative price strength of 11.89%, which translates to a Momentum Score of 82 and is considered to be Very Strong.

Want to learn more about how Pyxis Oncology, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Pyxis Oncology, Inc. Stock Price: Bottom Line

As of January 16, 2026, Pyxis Oncology, Inc.’s stock price is $1.925, which is up 4.64% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Pyxis Oncology, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.